Get Your Priority Review Voucher, While They Last
This article was originally published in RPM Report
Executive Summary
The approval of Retrophin/Asklepion’s Cholbam triggers the third pediatric rare disease priority review voucher – and the sunset provision in the statute authorizing the program.